Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Bissonnette R, et al. Among authors: xia s. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22. J Eur Acad Dermatol Venereol. 2018. PMID: 29444376 Free PMC article. Clinical Trial.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Bagel J, et al. Among authors: xia s. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8. J Eur Acad Dermatol Venereol. 2021. PMID: 32365251 Free PMC article. Clinical Trial.
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Thaçi D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, Blauvelt A. Thaçi D, et al. Among authors: xia s. J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6. J Am Acad Dermatol. 2019. PMID: 31399223 Free article. Clinical Trial. No abstract available.
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Bagel J, et al. Among authors: xia s. Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579. doi: 10.1007/s13555-018-0265-y. Epub 2018 Oct 17. Dermatol Ther (Heidelb). 2018. PMID: 30334147 Free PMC article.
Super-resolution ultrasound and microvasculomics: a consensus statement.
Xia S, Zheng Y, Hua Q, Wen J, Luo X, Yan J, Bai B, Dong Y, Zhou J; Chinese Artificial Intelligence Alliance for Thyroid and Breast Ultrasound. Xia S, et al. Eur Radiol. 2024 May 29. doi: 10.1007/s00330-024-10796-3. Online ahead of print. Eur Radiol. 2024. PMID: 38811389 Review.
4,140 results